Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review

References

• Shepard HM, Phillips GL, Thanos CD, et al. Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond). 2017;17(3):220–232.
   PubMed Web of Science ®Google Scholar
• Dobsch P, Michels B, Müller-Schilling M, et al. Therapeutic regimens using monoclonal antibodies in gastroenterology. Internist (Berl). 2019;60(10):1043–1058.
   PubMed Web of Science ®Google Scholar
• Tamilarasan AG, Cunningham G, Irving PM, et al. Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline Gastroenterol. 2019;10(4):409–416.
   PubMed Web of Science ®Google Scholar
• Kesharwani D, Paliwal R, Satapathy T, et al. Rheumatoid arthritis: an updated overview of latest therapy and drug delivery. J Pharmacopuncture. 2019;22(4):210–224.
   PubMed Web of Science ®Google Scholar
• Jeon C, Sekhon S, Yan D, et al. Monoclonal antibodies inhibiting IL-12, −23, and −17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13(10):2247–2259.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combinatino cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–584.
   PubMed Web of Science ®Google Scholar
• Posner J, Barrington P, Brier T, et al. Monoclonal antibodies: past, present and future. Handb Exp Pharmacol. 2019;260:81–141.
   PubMedGoogle Scholar
• Shanmugaraj B, Siriwattananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18.
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020;31;9:72.
   Google Scholar
• Buss NA, Henderson SJ, McFarlane M, et al. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12(5):615–622.
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–499.
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA. 1984;81(21):6851–6852.
   PubMed Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321(6069):522–535.
   PubMed Web of Science ®Google Scholar
• An Z. Monoclonal antibodies – a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell. 2010;1(4):319–330.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) [Internet]. European public assessment report. [ cited 2020 Mar 02]. Available from: https://www.ema.europa.eu/en/glossary/european-public-assessment-report
   Google Scholar
• Animal Cell Technology Industrial Platform (ACTIP) [Internet]. [ cited 2020 Jan 27]. Available from: https://www.actip.org/
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Listados de principios activos por grupos ATC e incorporación del pictograma de la conducción [Active principle lists by ATC goups and incorporation of the driving pictogram] [Internet]. [ cited 2020 Jan 27]. Available from: https://www.aemps.gob.es/industria/etiquetado/conduccion/listadosPrincipios/home.htm
   Google Scholar
• Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–3412.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125–1133.
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad, Consumo y Bienestar Social. Vacunación en grupos de riesgo de todas las edades y en determinadas situaciones, del programa y registro de vacunaciones, 2018 [Spanish Ministry of Health, Consumer Affairs and Social Welfare. Vaccination of risk goups of all ages and in specific circumstances, program and registry of vaccinations, 2018] [Internet]. [ cited 2020 Mar 02]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/VacGruposRiesgo/docs/VacGruposRiesgo_todas_las_edades.pdf
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). General Best Practice Guidelines for Immunization: best Practices Guidance. Altered Immunocompetence [Internet]. [ cited 2020 Mar 03]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP). Immunization schedules [Internet]. [ cited 2020 May 13]. Available from: https://www.cdc.gov/vaccines/schedules/hcp/adult.html
   Google Scholar
• Infectious Diseases Society of America (IDSA). Clinical practice guideline for vaccination of the immunocompromised host. 2013 [Internet]. [cited 2020 Mar 03]. Available from: https://www.idsociety.org/practice-guideline/vaccination-of-the-immunocompromised-host/
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318.
   PubMed Web of Science ®Google Scholar
• Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10–27.
   PubMed Web of Science ®Google Scholar
• Bahuaud M, Beaudouin-Bazire C, Husson M, et al. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. Hum Vaccin Immunother. 2018;14(6):1464–1470.
   PubMed Web of Science ®Google Scholar
• Nguyen MTT, Lindegaard H, Hendricks O, et al. Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: results of a randomized controlled trial. J Rheumatol. 2017;44(12):1794–1803.
   PubMed Web of Science ®Google Scholar
• Nived P, Saxne T, Geborek P, et al. Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment. BMC Rheumatol. 2018;2:12.
   PubMedGoogle Scholar
• Kantsø B, Halkjær SI, Thomsen OØ, et al. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn’s disease. Vaccine. 2015;33(41):5464–5469.
   PubMed Web of Science ®Google Scholar
• Caporuscio S, Ieraci R, Valesini G, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018;195:18–27.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Schechtman J, Texter M, et al. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol. 2014;41(4):648–657.
   PubMed Web of Science ®Google Scholar
• Mehta L, Umans K, Ozen G, et al. Immune response to seasonal Influenza vaccine in patients with relapsing-remitting multiple sclerosis receiving long-term daclizumab beta: a prospective, open-label, single-arm study. Int J MS Care. 2017;19(3):141–147.
   PubMedGoogle Scholar
• Kaufman M, Pardo G, Rossman H, et al. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014;341(1–2):22–27.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al.; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33(2):388–396.
   PubMed Web of Science ®Google Scholar
• van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81.
   PubMed Web of Science ®Google Scholar
• Berglund A, Willén L, Grödeberg L, et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol. 2014;53(9):1212–1220.
   PubMed Web of Science ®Google Scholar
• Bingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818–822.
   PubMed Web of Science ®Google Scholar
• Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24(3):511–516.
   PubMed Web of Science ®Google Scholar
• Brodmerkel C, Wadman E, Langley RG, et al. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013;12(10):1122–1129.
   PubMed Web of Science ®Google Scholar
• Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Immunization in Immunocompromised Children. Report of the Committee on Infectious Diseases. Red Book®; 2015. p. 74–89.
   Google Scholar
• Asociación Española de Pediatría (AEP). Comité Asesor de Vacunas. Vacunación en niños inmunodeprimidos o con tratamiento inmunosupresor. Manual de Vacunas en línea de la AEP. Capítulo 14. [Spanish Pediatrics Association (AEP). Vaccine Advisory Committee. Vaccination in immunosuppressed children or children under immunosuppressive therapy. AEP Online immunization manual. Chapter 14.] [Internet]. [ cited 2020 Mar 03]. Available from: http://vacunasaep.org/print/documentos/manual/cap-14
   Google Scholar
• Public Health England. Immunisation against infectious diseases: immunisation of individuals with underlying medical conditions. Salisbury: The Green Book. The Stationary Office; 2016.
   Google Scholar
• Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th ed (2017 update). Canberra: Australian Government Department of Health, 2017. Part 3.3.3 Vaccination of immunocompromised persons [Internet] [ cited 2020 Mar 03]. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part3~handbook10-3-3#3-3-3
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318.
   PubMed Web of Science ®Google Scholar
• Liao Z, Tang H, Xu X, et al. Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis. PLoS One. 2016;11(2):e0147856.
   PubMed Web of Science ®Google Scholar
• Lebrun C, Vukusic S. French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SFSEP). Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019;31:173–188.
   PubMed Web of Science ®Google Scholar
• Richi P, Martín MD, Navío MT, et al. Antibody responses to influenza vaccine in patients on biological therapy: results of RIER cohort study. Med Clin (Barc). 2019;153(10):380–386.
   PubMed Web of Science ®Google Scholar
• Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother. 2018;14(6):1311–1322.
   PubMed Web of Science ®Google Scholar
• Natori Y, Humar A, Lipton J, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017;52(7):1016–1021.
   PubMed Web of Science ®Google Scholar
• Manuel O, Humar A, Chen MH, et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant. 2007;7(11):2567–2572.
   PubMed Web of Science ®Google Scholar
• Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64(7):829–838.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang H, Tam WWS. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Curr Med Res Opin. 2017;33(10):1901–1908.
   PubMed Web of Science ®Google Scholar
• Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206(8):1250–1259.
   PubMed Web of Science ®Google Scholar
• Schmoele-Thoma B, van Cleeff M, Greenberg RN, et al. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Hum Vaccin Immunother. 2019;15(3):575–583.
   PubMed Web of Science ®Google Scholar
• Rákóczi É, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017;3(2):e000484.
   PubMed Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–1026.
   PubMed Web of Science ®Google Scholar
• Alten R, Bingham CO 3rd, Cohen SB, et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016;17:231.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042–1047.
   PubMed Web of Science ®Google Scholar
• Nagel J, Saxne T, Geborek P, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017;26(10):1072–1081.
   PubMed Web of Science ®Google Scholar
• Lewis E, Shinefield HR, Woodruff BA, et al. Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J. 2001;20(11):1049–1054.
   PubMed Web of Science ®Google Scholar
• DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev Vaccines. 2002;1(4):461–466.
   PubMedGoogle Scholar
• Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine. 1998;16(7):708–714.
   PubMed Web of Science ®Google Scholar
• Intongkam S, Samakarnthai P, Pakchotanon R, et al. Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. J Clin Rheumatol. 2019;25(8):329–334.
   PubMed Web of Science ®Google Scholar
• Karaman S, Vural S, Yildirmak Y, et al. Assessment of hepatitis B immunization status after antineoplastic therapy in children with cancer. Ann Saudi Med. 2011;31(6):573–576.
   PubMed Web of Science ®Google Scholar
• Van Den Ende C, Marano C, Van Ahee A, et al. The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. Expert Rev Vaccines. 2017;16(8):811–832.
   PubMed Web of Science ®Google Scholar
• Rodrigues IC, Silva RCMAD, Felício HCC, et al. New immunization schedule effectiveness against hepatitis B in liver transplantation patients. Arq Gastroenterol. 2019;56(4):440–446.
   PubMedGoogle Scholar
• Bonazzi PR, Bacchella T, Freitas AC, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis. 2008;12(4):306–309.
   PubMed Web of Science ®Google Scholar
• Günther M, Neuhaus R, Bauer T, et al. Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transpl. 2006;12(2):316–319.
   PubMed Web of Science ®Google Scholar
• Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine nonresponders: possible mechanisms and solutions. Ann Allergy Asthma Immunol. 2018;121(3):320–327.
   PubMed Web of Science ®Google Scholar
• Walayat S, Ahmed Z, Martin D, et al. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7(24):2503–2509.
   PubMed Web of Science ®Google Scholar
• Choi J, Lim YS. Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy. J Infect Dis. 2017;216(S8):S778–S884.
   PubMed Web of Science ®Google Scholar
• Chen MH, Chen MH, Liu CY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2017;215(4):566–573.
   PubMed Web of Science ®Google Scholar
• Paul S, Saxena A, Terrin N, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164(1):30–40.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B reactivation during immunosuppressive drug therapy. Gastroenterol. 2015;148(1):221–244.
   PubMed Web of Science ®Google Scholar
• Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis. 2018;5(8):ofy174.
   PubMed Web of Science ®Google Scholar
• Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46(9):1459–1465.
   PubMed Web of Science ®Google Scholar
• Tran-Minh ML, Sousa P, Maillet M, et al. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol. 2017;9(13):613–626.
   PubMed Web of Science ®Google Scholar
• Asociación Española de Pediatría (AEP). Comité asesor de vacunas. Vacunación en niños inmunodeprimidos o con tratamiento inmunosupresor. [Spanish Pediatrics Association (AEP). Vaccine Advisory Committee. Vaccination in immunosuppressed children or children under immunosuppressive therapy] [Internet]. [ cited 2020 May 20]. Available from: https://vacunasaep.org/documentos/manual/cap-14#3.3.4
   Google Scholar
• Government of Canada. Update on the recommended use of hepatitis A vaccine. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) [Internet]. [ cited 2020 May 20]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-vaccine.html
   Google Scholar
• Wine-Lee L, Keller SC, Wilck MB, et al. From the medical board of the national psoriasis foundation: vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003–1013.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. Sullivan, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Meca-Lallana JE, Fernández-Prada M, García Vázquez E, et al. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia. 2020;S0213–4853(19)30146-X.
   Google Scholar
• Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015;14(8):1047–1049.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang J, Xia N, et al. Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2017;13(10):2280–2291.
   PubMed Web of Science ®Google Scholar
• Wnukowski-Mtonga P, Jayasinghe S, Chiu C, et al. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia. Commun Dis Intell. 2018;2020:44.
   Google Scholar
• Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–133.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59(7):913–919.
   PubMed Web of Science ®Google Scholar
• Vink P, Delgado Mingorance I, Maximiano Alonso C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer. 2019;125(8):1301–1312.
   PubMed Web of Science ®Google Scholar
• Parrino J, McNeil SA, Lawrence SJ, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine. 2017;35(14):1764–1769.
   PubMed Web of Science ®Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terapéutico de cladribina (Mavenclad®) en esclerosis múltiple [Spanish Agency for Medicines and Health Products. Therapeutic positioning report of cladribine (Mavenclad®) in multiple sclerosis] [Internet]. [ cited 2020 May 20]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-cladribina-Mavenclad-esclerosis-multiple.pdf?x17133
   Google Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038.
   PubMed Web of Science ®Google Scholar
• Havers FP, Moro PL, Hunter P, et al. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the advisory committee on immunization practices - United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(3):77–83.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Department of Violence and Injury Prevention and Disability. Prevention and management of wound infection [Internet]. [ cited 2020 May 20]. Available from: https://www.who.int/hac/techguidance/tools/guidelines_prevention_and_management_wound_infection.pdf
   Google Scholar
• Danziger-Isakov L, Kumar D. AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):311–317.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Donath S, Perrett KP, et al. The influence of neonatal Bacille Calmette-Guérin (BCG) immunisation on heterologous vaccine responses in infants. Vaccine. 2019;37(28):3735–3744.
   PubMed Web of Science ®Google Scholar
• de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis. 2015;60(11):1611–1619.
   PubMed Web of Science ®Google Scholar
• Butkeviciute E, Jones CE, Smith SG. Heterologous effects of infant BCG vaccination: potential mechanisms of immunity. Future Microbiol. 2018;13(10):1193–1208.
   PubMed Web of Science ®Google Scholar
• Kowalewicz-Kulbat M, Locht C. BCG and protection against inflammatory and auto-immune diseases. Expert Rev Vaccines. 2017;16(7):1–10.
   PubMed Web of Science ®Google Scholar
• Bühler S, Eperon G, Ribi C, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.
   PubMed Web of Science ®Google Scholar
• Löbermann M, Boršo D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11(3):212–218.
   PubMed Web of Science ®Google Scholar